Antiresorptive agent-related osteonecrosis of the jaw in prostate cancer patients with bone metastasis treated with bone-modifying agents.

Yasutomo NakaiTomohiro KanakiAkinaru YamamotoRyo TanakaYoshiyuki YamamotoAkira NagaharaMasashi NakayamaKen-Ichi KakimotoMiki IshibashiKazuo Nishimura

Published in: Journal of bone and mineral metabolism (2020)

Almost one-quarter of patients had a risk of developing ARONJ within 5 years after starting BMA. Low serum calcium, use of chemotherapeutic agents, and use of denosumab might contribute to the development of ARONJ.

Keyphrases

prostate cancer
bone mineral density
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
soft tissue
peritoneal dialysis
radical prostatectomy
bone loss
patient reported